Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. (PHIO) director Ronald Todd Plott reported an open-market or private purchase of company stock. On 2026-08-19, he bought 15,000 shares of common stock at $1.14 per share. Following this transaction, he directly holds 15,000 shares of Phio Pharmaceuticals common stock.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Plott Ronald Todd

Role Director

Bought 15,000 shs ($17K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, $.0001 par value	15,000	$1.14	$17K

Holdings After Transaction: Common Stock, $.0001 par value — 15,000 shares (Direct)

Key Figures

Shares purchased: 15,000 shares Purchase price: $1.14 per share Shares owned after transaction: 15,000 shares +1 more

4 metrics

Shares purchased 15,000 shares Common Stock, $.0001 par value, acquired on 2026-08-19

Purchase price $1.14 per share Price for the 15,000-share purchase on 2026-08-19

Shares owned after transaction 15,000 shares Total direct holdings of Ronald Todd Plott following the reported purchase

Net buy shares 15,000 shares Net buy direction across all transactions in this Form 4

Key Terms

Form 4, open market or private transaction, direct ownership

3 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open market or private transaction market

"transaction_code_description": "Purchase in open market or private transaction""

direct ownership financial

""ownership_type": "direct""

FAQ

What insider transaction did PHIO director Ronald Todd Plott report?

Ronald Todd Plott reported a purchase of Phio Pharmaceuticals (PHIO) common stock. He acquired 15,000 shares in an open-market or private transaction on 2026-08-19.

How many PHIO shares did Ronald Todd Plott buy and at what price?

Ronald Todd Plott bought 15,000 PHIO shares at a price of $1.14 per share. The transaction was reported as a purchase in an open-market or private transaction.

What is Ronald Todd Plott’s total PHIO shareholding after this Form 4 transaction?

After the reported transaction, Ronald Todd Plott directly owns 15,000 shares of Phio Pharmaceuticals (PHIO) common stock. This post-transaction holding equals the number of shares purchased in this filing.

Was the PHIO insider transaction by Ronald Todd Plott a buy or a sell?

The transaction was a buy. Ronald Todd Plott purchased 15,000 shares of Phio Pharmaceuticals (PHIO) common stock in an open-market or private transaction on 2026-08-19.

Is the PHIO Form 4 transaction by Ronald Todd Plott under a Rule 10b5-1 plan?

The transaction is not indicated as being under a Rule 10b5-1 trading plan. The filing’s Rule 10b5-1 checkbox is marked false, and no footnote describes a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 08:30 AM Accepted by SEC EDGAR 08/20/2026 - 08:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plott Ronald Todd

(Last) (First) (Middle)

C/O PHIO PHARMACEUTICALS CORP

411 SWEDELAND RD., STE 23-1080

(Street)

KING OF PRUSSIA PENNSYLVANIA 19406

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.0001 par value	08/19/2026		P		15,000	A	$1.14	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lisa C. Carson attorney-in-fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)